NASDAQ · Biotechnology

ARVN (ARVN) Stock

$8.02 -3.43% NASDAQ: ARVN Healthcare

Valuation

MetricValue
Price$8.02
Market Cap$517.14M
P/E Ratio-6.94
P/B Ratio1.32
P/S Ratio6.57
EPS (TTM)$0.00
52-Week High$14.51
52-Week Low$6.06
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-18.66%
ROA-11.28%
ROCE-26.50%
Gross Margin-43.73%
Operating Margin-43.73%
Net Margin-2.48%
Debt/Equity0.02
Current Ratio4.90

Annual Financials (USD)

Metric20212022202320242025
Revenue$54.0M$131.0M$79.0M$263.0M$263.0M
Operating Profit$-188.0M$-263.0M$-401.0M$-250.0M$-115.0M
Net Profit$-191.0M$-282.0M$-367.0M$-199.0M$-81.0M
EPS$-3.82$-5.31$-6.62$-2.77$-1.28
Op Margin-351.5%-200.3%-511.5%-95.0%-43.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.6B$1.3B$1.3B$1.1B$718.0M
Total Liabilities$800.0M$704.0M$645.0M$530.0M$284.0M
Cash$108.0M$81.0M$312.0M$101.0M$143.0M
Borrowings$5.0M$6.0M$3.0M$10.0M$9.0M

Latest News

uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock? Zacks · Jun 18, 2026 Rigel Pharmaceuticals Closes Licensing Deal for Breast Cancer Drug Veppanu MT Newswires · Jun 16, 2026 Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant) PR Newswire · Jun 16, 2026 Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains? Zacks · Jun 12, 2026 Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data MarketBeat · Jun 5, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$559.0M$-273.0M$-348.0M$-259.0M$-274.0M
Investing Cash Flow$-1.3B$236.0M$201.0M$33.0M$406.0M
Financing Cash Flow$14.0M$0$0$0$-92.0M
Net Cash Flow$-476.0M$-26.0M$230.0M$-217.0M$42.0M
Free Cash Flow$555.0M$-280.0M$-351.0M$-261.0M$-276.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-43.71%
Quick Ratio5.44
Interest Coverage—
Return 1Y3.18%
Return 3Y-65.65%
Return 5Y-88.70%

Ownership

Insiders Held7.91%
Institutions Held82.59%
Institutions Float Held89.68%
Institutional HolderSharesReport Date
Blackrock Inc.6,797,5842026-03-31
Vanguard Portfolio Management LLC3,889,6282026-03-31
Shaw D.E. & Co., Inc.3,638,5672026-03-31
Pfizer Inc3,457,8152026-03-31
Vanguard Capital Management LLC2,689,3622026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATXSAstria Therapeutics, Inc. $12.58 +0.00% -7.40 $718.13M 0.00%
AVBP $30.84 -0.55% -8.82 $1.44B 0.00%
DAWNDay One Biopharmaceuticals, Inc. $21.53 +0.00% -20.70 $2.22B 0.00%
DNA $8.07 -0.19% -1.30 $527.50M 0.00%
ERAS $17.72 -2.42% -23.45 $6.15B 0.00%

About ARVN

ARVN is led by CEO Randy Teel, employs 430 people, headquartered in US, publicly traded since 2018.

ARVN stock trades at $8.02 with a market capitalization of $517.14M. The stock is valued at a price-to-earnings (P/E) ratio of -6.94, price-to-book of 1.32, price-to-sales of 6.57. Over the past 52 weeks the stock has ranged between $6.06 and $14.51, and currently trades 44.7% below its 52-week high.

On profitability, ARVN generates a return on equity (ROE) of -18.66%, return on capital employed of -26.50%, an operating margin of -43.73%, a net profit margin of -2.48%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides